Methods of administering elagolix
AssigneeAbbVie Inc.
InventorsSandra L. Goss, Cheri E. Klein, Juki Wing-Keung Ng, Ahmed Salem
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
Claims22
A method of treating endometriosis, the method comprising the administration of elagolix at a dose of 150 mg once per day, the method further comprising the co-administration of rifampin, wherein after the co-administration of rifampin, the patient is treated with a dose of elagolix less than 150 mg once per day by reducing the amount of elagolix or by increasing the interval between doses or a combination thereof.
A method of treating endometriosis, the method comprising the administration of elagolix at a dose of 200 mg b.i.d., the method further comprising the co-administration of rifampin, wherein after the co-administration of rifampin, the patient is treated at a dose of elagolix less than 200 mg b.i.d. by reducing the amount of elagolix and/or by increasing the interval between doses.
A method of treating a patient for uterine fibroids, the method comprising the administration of elagolix at 300 mg b.i.d., the method further comprising the co-administration of rifampin, wherein after the co-administration of rifampin, the patient is treated with a dose of elagolix less than 300 mg b.i.d. by reducing the amount of elagolix or by increasing the interval between doses or a combination thereof.
A method of treating an endometriosis patient comprising the administration of elagolix according to a first dosing schedule and wherein;
- said patient subsequently begins to take rifampin according to a rifampin dosing schedule;
- and wherein said patient adjusts the first dosing schedule of elagolix by reducing the amount of elagolix and/or by increasing the interval between doses according to a second dosing schedule;
- wherein said second dosing schedule results in overall reduced elagolix exposure in the second dosing schedule relative to elagolix exposure in the first dosing schedule for a given time interval.
A method of treating an uterine fibroid patient comprising the administration of elagolix according to a first dosing schedule and wherein;
- said patient subsequently begins to take rifampin according to a rifampin dosing schedule;
- and wherein said patient adjusts the first dosing schedule of elagolix by reducing the amount of elagolix and/or by increasing the interval between doses according to a second dosing schedule;
- wherein said second dosing schedule results in overall reduced elagolix exposure in the second dosing schedule relative to elagolix exposure in the first dosing schedule for a given time interval.
Dependencies are inferred from the claim text.